ENSA-1 in ASEL promotes glucose attraction and Na⁺ avoidance after glucose conditioning. by Masahiro Tomioka (430683)

Average PAM response waveforms for monaural and binaural conditions. by T. P. Doubell (5059220)

Figure 2. Deletion of Arrb1 attenuates the VEGF-C/VEGFR3 signaling in mice exposed to hypoxia. by Zhiyuan Ma (6441500)

“…(<b>d</b>) Protein expression in lung lystates from WT, <i>Arrb1</i> KO, and <i>Arrb2</i> KO mice (n = 3 mice per group). Quantification and normalization to WT exposed to normoxia demonstrates (<b>e</b>) a significant decrease in VEGFR3 and Akt phosphorylation in <i>Arrb1</i> KO mice. …”

Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Sample cases of each type of visual field defect. by Kyoung Min Lee (677987)

Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase by Safiatou T. Coulibaly (816058)

“…Importantly, a remarkable effect is also observed in treatments with the anticancer compound cytarabine (AraC), for which a 10,000 fold decrease in IC50 occurred. …”

Effects of SQFZ or SQFZ + cisplatin on tumour growth in MDA-MB-231/DDP+M2 xenografts. by Bin Yan (32980)

Scatter plot according to the type of ODD. by Kyoung Min Lee (677987)

Types of visual field defects. by Kyoung Min Lee (677987)

Both cell migration and invasion decrease with decreasing SP1 in SNU484 diffuse-type gastric carcinoma cells, and transcription of genes related to cell proliferation or migration... by Hun Seok Lee (378431)

Image_2_Baseline Testosterone Predicts Body Composition and Metabolic Response to Testosterone Therapy.jpeg by FNU Deepika (11881310)

“…Men with T ≥ 264 ng/dl showed significant decreases in HbA1c at 12 months (−3.1 ± 9.2 vs. 3.2 ± 13.9%; p = 0.005), fasting glucose at 18 months (−4.2 ± 31.9 vs. 13.0 ± 57.3%; p = 0.040), LDL at 6 months (−6.4 ± 27.5 vs. 12.8 ± 44.1%; p = 0.034), and leptin at 18 months (−40.2 ± 35.1 vs. −27.6 ± 31.0%; p = 0.034) compared to those with T < 264 ng/dl. …”

Crystallographic structure of SVA 3C^pro in complex with the physiological substrate. by Hai-Fan Zhao (15990862)

Visibility of the rhabdomeric membrane from the soma and membrane capacitance. by Roman V. Frolov (9647905)

L1 starvation activates AAK-2 partially depending on PAR-4, <i>C. elegans</i> LKB1. by Inhwan Lee (136973)

“…C. AAK-2 is phosphorylated in response to starvation and mitochondrial poisoning with NaN₃ in a partially PAR-4 dependent manner. …”

Elementary trends on the time series for the prices of the DJIA during the period from Oct/30/1978 to Jan/09/1979. by Héctor Raúl Olivares-Sánchez (13014866)

OP2113 improves the recovery of the contractile performance of Langendorff-perfused rat heart during the reperfusion phase following ischemia. by Dominique Detaille (3768979)

Phloem transport capacity of transgenic rice T1c-19 (<i>Cry1C*</i>) under several potassium fertilizer levels by Lin Ling (296367)

“…Results presented that the mean setting rate and grain yield of T1c-19 (<i>Cry1C*</i>) decreased by 22.3% and 26.2% compared to those in MH63, respectively. …”

Cytoskeletal Drugs Modulate Off-Target Protein Folding Landscapes Inside Cells by Caitlin M. Davis (5642156)